Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION CANOPY-1 Ph3 data support further evaluation of canakinumab in lung cancer CANOPY-1 ■ Did not meet primary endpoints: OS and PFS in previously untreated locally advanced or metastatic NSCLC1 Potentially clinically meaningful improvements in both PFS and OS among pre-specified subgroups of patients with inflammatory biomarkers; additional analyses ongoing1 ■ Results support continued study of canakinumab in earlier stages of lung cancer, further evaluation of Pro-Tumor Inflammation in all lung cancer settings¹. ■ CANOPY-A study more closely reflect the CANTOS study population vs. CANOPY-12,3,4. CANTOS the 1st study to suggest that IL-1ẞ inhibition may play a role in lung cancer³ ■ No unexpected safety signals when combined with pembrolizumab plus platinum-based chemotherapy Study CANOPY-2 2/3 L NSCLC CANOPY-1 1L NSCLC CANOPY-A Adjuvant NSCLC Patient population Metastatic NSCLC treatment failed. Canakimumab with docetaxel Metastatic NSCLC, treatment naive. Canakimumab combined with pembrolizumab Stage II-III NSCLC. Canakimumab after complete resection and adjuvant chemotherapy CANTOS Stable post MI with elevated hsCRP > 2mg/L Hypothesis Reduce progression of treatment resistant tumors Reduce progression of treatment naive tumors Reduce development of tumors from micro- metastatic disease. Findings Primary endpoint OS not met. No benefit observed. Primary endpoints of OS + PFS not statistically significant. Potentially clinically meaningful OS +PFS improvements in pre-specified subgroups (hs-CRP, other biomarker- defined subgroups) To be determined Alter tumor development in high risk population Dose-dependent reduction in fatal/non-fatal lung cancer incidence Developing other potential pro-tumor inflammation pathway inhibitors, which are at various stages of development, incl. gevokizumab5,6 See appendix for references NSCLC Non-small cell lung cancer OS - Overall survival PFS - Progression-free survival 21 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation